These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38293112)

  • 41. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Modular design of synthetic receptors for programmed gene regulation in cell therapies.
    Zhu I; Liu R; Garcia JM; Hyrenius-Wittsten A; Piraner DI; Alavi J; Israni DV; Liu B; Khalil AS; Roybal KT
    Cell; 2022 Apr; 185(8):1431-1443.e16. PubMed ID: 35427499
    [TBL] [Abstract][Full Text] [Related]  

  • 44. SARS-CoV-2-specific CD8
    Rowntree LC; Petersen J; Juno JA; Chaurasia P; Wragg K; Koutsakos M; Hensen L; Wheatley AK; Kent SJ; Rossjohn J; Kedzierska K; Nguyen TH
    Immunol Cell Biol; 2021 Oct; 99(9):990-1000. PubMed ID: 34086357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation.
    Dragon AC; Zimmermann K; Nerreter T; Sandfort D; Lahrberg J; Klöß S; Kloth C; Mangare C; Bonifacius A; Tischer-Zimmermann S; Blasczyk R; Maecker-Kolhoff B; Uchanska-Ziegler B; Abken H; Schambach A; Hudecek M; Eiz-Vesper B
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33127653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The Principles of Engineering Immune Cells to Treat Cancer.
    Lim WA; June CH
    Cell; 2017 Feb; 168(4):724-740. PubMed ID: 28187291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses.
    Carnell GW; Ciazynska KA; Wells DA; Xiong X; Aguinam ET; McLaughlin SH; Mallery D; Ebrahimi S; Ceron-Gutierrez L; Asbach B; Einhauser S; Wagner R; James LC; Doffinger R; Heeney JL; Briggs JAG
    J Virol; 2021 Jul; 95(15):e0020321. PubMed ID: 33963055
    [TBL] [Abstract][Full Text] [Related]  

  • 48. De novo design and Rosetta-based assessment of high-affinity antibody variable regions (Fv) against the SARS-CoV-2 spike receptor binding domain (RBD).
    Boorla VS; Chowdhury R; Ramasubramanian R; Ameglio B; Frick R; Gray JJ; Maranas CD
    Proteins; 2023 Feb; 91(2):196-208. PubMed ID: 36111441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8
    Minervina AA; Pogorelyy MV; Kirk AM; Crawford JC; Allen EK; Chou CH; Mettelman RC; Allison KJ; Lin CY; Brice DC; Zhu X; Vegesana K; Wu G; Trivedi S; Kottapalli P; Darnell D; McNeely S; Olsen SR; Schultz-Cherry S; Estepp JH; ; McGargill MA; Wolf J; Thomas PG
    Nat Immunol; 2022 May; 23(5):781-790. PubMed ID: 35383307
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: towards tumor-directed oligoclonal T cell therapy.
    Jamnani FR; Rahbarizadeh F; Shokrgozar MA; Mahboudi F; Ahmadvand D; Sharifzadeh Z; Parhamifar L; Moghimi SM
    Biochim Biophys Acta; 2014 Jan; 1840(1):378-86. PubMed ID: 24076235
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Structural basis of biased T cell receptor recognition of an immunodominant HLA-A2 epitope of the SARS-CoV-2 spike protein.
    Chaurasia P; Nguyen THO; Rowntree LC; Juno JA; Wheatley AK; Kent SJ; Kedzierska K; Rossjohn J; Petersen J
    J Biol Chem; 2021 Sep; 297(3):101065. PubMed ID: 34384783
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond.
    Chang ZL; Chen YY
    Trends Mol Med; 2017 May; 23(5):430-450. PubMed ID: 28416139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Multiepitope Proteins for the Differential Detection of IgG Antibodies against RBD of the Spike Protein and Non-RBD Regions of SARS-CoV-2.
    Gomes LR; Durans AM; Napoleão-Pêgo P; Waterman JA; Freitas MS; De Sá NBR; Pereira LV; Furtado JS; Aquino RG; Machado MCR; Fintelman-Rodrigues N; Souza TML; Morel CM; Provance DW; De-Simone SG
    Vaccines (Basel); 2021 Sep; 9(9):. PubMed ID: 34579223
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein.
    Girt GC; Lakshminarayanan A; Huo J; Dormon J; Norman C; Afrough B; Harding A; James W; Owens RJ; Naismith JH
    R Soc Open Sci; 2021 Sep; 8(9):211016. PubMed ID: 34631127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effective chimeric antigen receptor T cells against SARS-CoV-2.
    Guo X; Kazanova A; Thurmond S; Saragovi HU; Rudd CE
    iScience; 2021 Nov; 24(11):103295. PubMed ID: 34693218
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthetic Biology in Chimeric Antigen Receptor T (CAR T) Cell Engineering.
    Zhang C; Zhuang Q; Liu J; Liu X
    ACS Synth Biol; 2022 Jan; 11(1):1-15. PubMed ID: 35005887
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Robust immune responses to SARS-CoV-2 in a pediatric patient with B-Cell ALL receiving tisagenlecleucel.
    Gordon OM; Terpilowski M; Dulman R; Keller MD; Burbelo PD; Cohen JI; Bollard CM; Dave H
    Pediatr Hematol Oncol; 2022 Sep; 39(6):571-579. PubMed ID: 35135442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
    Stock S; Benmebarek MR; Kluever AK; Darowski D; Jost C; Stubenrauch KG; Benz J; Freimoser-Grundschober A; Moessner E; Umana P; Subklewe M; Endres S; Klein C; Kobold S
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Biomaterials for chimeric antigen receptor T cell engineering.
    Niu H; Zhao P; Sun W
    Acta Biomater; 2023 Aug; 166():1-13. PubMed ID: 37137403
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Engineered Cell-Based Therapeutics: Synthetic Biology Meets Immunology.
    Caliendo F; Dukhinova M; Siciliano V
    Front Bioeng Biotechnol; 2019; 7():43. PubMed ID: 30937303
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.